Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $40,914.60 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard William Scalzo also recently made the following trade(s):

• On Wednesday, September 18th, Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50.

Dyne Therapeutics Stock Up 0.5 %

Shares of DYN stock opened at $25.73 on Friday. The stock has a 50-day simple moving average of $30.39 and a 200 day simple moving average of $35.20. The stock has a market capitalization of $2.62 billion, a P/E ratio of -7.23 and a beta of 1.09. Dyne Therapeutics, Inc. has a fifty-two week low of $11.51 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares during the period. Janus Henderson Group PLC lifted its stake in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after buying an additional 2,189,339 shares in the last quarter. State Street Corp boosted its holdings in shares of Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares during the period. RTW Investments LP increased its position in shares of Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after acquiring an additional 431,503 shares in the last quarter. Finally, RA Capital Management L.P. raised its holdings in shares of Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. StockNews.com lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Royal Bank of Canada began coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 target price on the stock. Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday. They set an “outperform” rating and a $46.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.